CClinicalTrials.gg
RecruitingNCT05589831Updated Mar 24, 2025

Respiratory Support and Brain Health in Preterm Infants

An observational study in Sleep and Cerebral Oxygenation, sponsored by Mount Sinai Hospital, Canada. Recruiting at 1 site in Canada. Open to participants aged 3 Days and older. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Mount Sinai Hospital, Canada · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.
Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
50
Ages
3 Days and older
Sex
All
01

Study summary

Premature babies often require breathing support during their neonatal intensive care unit stay. This is because their lungs are not fully developed to perform the work of breathing on their own. Although breathing support can be provided via a breathing tube, it is preferable to provide breathing support non-invasively from a breathing machine which is then connected to a mask or prongs placed on the baby's nose. In premature babies born under 32 weeks gestation, a commonly used mode of non-invasive breathing support is called Non-Invasive Positive Pressure Ventilation (NIPPV). In this mode, the breathing machine provides 2 levels of support: one is the constant distending pressure to keep the lungs open and the other provides additional 'breaths' on top of that distending pressure. This is to mimic regular breathing. These breaths are set at a fixed rate and pressure. Although NIPPV protects the lungs from injury caused by a breathing tube, the breaths are not in sync with the baby's own breathing effort. Another mode of non-invasive breathing support recently being used in premature infants called Neurally Adjusted Ventilatory Assist (NAVA). When NAVA is provided non-invasively using a mask or prongs similar to NIPPV, it is called Non-invasive NAVA (NIV-NAVA). During NIV-NAVA a special feeding tube is used that detects the baby's own breathing movement from the electrical signal of the baby's diaphragm and feeds back to the machine which then provides a 'top-up' to the baby's own breath. This top-up breath also provides only as much pressure as the baby needs on top on their own breathing effort. Therefore, this is thought to be in sync with the baby's own breathing effort. However, it is not known if this mode of ventilation leads to improved sleep, improved brain oxygen levels, reduced discomfort and improved functioning of the diaphragm. The investigators aim to examine these indices in this research project.

Read the detailed description

Rationale: It is imperative to find the optimal method of supporting not only lung development, but also brain development during this critical period of brain growth and development. NIV-NAVA is a more physiologically compatible method of supporting respiration. The investigators hypothesize that this compatibility may increase comfort and restful periods compared to standard NIPPV, and thus, may be more neuroprotective.

Objective and outcomes assessed: The objective is to compare sleep-wake cycling, cerebral oxygenation, heart rate variability and diaphragm function during standard NIPPV and NIV-NAVA modes in preterm neonates born at \<32 weeks' gestation who are stable on NIPPV or NIV-NAVA for at least 24 hours and are a minimum of 3 days old.

02

Conditions studied

  • Sleep
  • Cerebral Oxygenation

Browse trials for

Keywords

  • Neurally Adjusted Ventilatory Assist
  • Non-Invasive Positive Pressure Ventilation
  • Preterm Neonates
  • Amplitude integrated electroencephalography
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's planned enrollment of 50 is below the median of 112 across 777 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

Mount Sinai Hospital, Canada is the lead sponsor of 157 studies on the registry; 33 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Days and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Preterm infants at tertiary NICU at Mount Sinai Hospital (Toronto, Ontario).

Inclusion criteria

  • Preterm infants born between 22+0 and 31+6 weeks' GA
  • Weight > 500 g at the time of approach for consent
  • A minimum of 3 days of age
  • Clinically stable for > 24 hours while receiving NIPPV or NIV-NAVA

Clinical stability will be defined as meeting all the following criteria for a 24 hour period prior to recruitment:

  1. differences in maximum and minimum fractions of inspired oxygen (FiO2) of \<20%
  2. differences in maximum and minimum MAP \<4 cm H2O
  3. no active infection
  4. no hypotension
  5. no use of cardioactive medications or medical therapy for patent ductus arteriosus.

Exclusion criteria

Exclusion Criteria:

  • Infants with IVH of grade 3 or 4
  • Birth weight \< 3rd percentile
  • Genetic or congenital abnormalities
05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • DeviceNon-invasive Neurally Adjusted Ventilatory Assist

    Neurally Adjusted Ventilatory Assist (NAVA) is a new non-invasive ventilation mode that uses the electrical activity of the diaphragm (EAdi) to offer ventilatory assistance in synchrony with patient effort, thus potentially reducing stress and discomfort. It uses electrodes placed on a modified nasogastric feeding tube to detect the electrical activity of the diaphragm (EAdi), such that both the initiation and termination of a breath during each respiratory cycle is in synchrony with the infant's effort

    Also known as: NIV-NAVA

06

What researchers measure

Primary outcomes

  1. Number of uninterrupted sleep-wake cycling (SWC)

    An uninterrupted SWC will be defined as a smooth and gradual decrease in the minimum amplitude on aEEG to quiet sleep (QS), followed by a gradual increase to active sleep or awake state (AS). An interrupted SWC will be defined as a sudden or sharp increase in the minimum amplitude during QS with change to AS state that may or may not be followed by a further drop in QS.

    Time frame: For 24 hours after intervention initiation

Secondary outcomes

  1. Total duration of quiet sleep (QS)

    First, high base voltage (HBV) will be defined as the voltage of the lower margin of aEEG during AS. Total QS duration will be calculated as the combined duration of time spent below the HBV in uninterrupted SWC during 24 h.

    Time frame: For 24 hours after intervention initiation

  2. Cerebral oxygen saturation (CrSO2)

    Cerebral fractional tissue oxygen extraction (CFTOE), calculated as (oxygen saturation \[SpO2\] - CrSO2) / SpO2, will be calculated offline

    Time frame: For 24 hours after intervention initiation

  3. Newborn Infant Parasympathetic Evaluation (NIPE) index

    Measurement of heart rate variability

    Time frame: For 24 hours after intervention initiation

  4. Diaphragmatic thickness

    Measurement of Diaphragmatic thickness (DT) using lung ultrasound

    Time frame: 1 day during Nasal Intermittent Positive-Pressure Ventilation (NIPPV) period and 1 day during the Non-Invasive Neurally Adjusted Ventilatory Assist (NIV-NAVA) period

  5. Diaphragm thickness fraction

    Diaphragmatic thickness fraction (DTF), calculated as (\[(inspiratory thickness-expiratory thickness)\]) / (expiratory thickness) x 100, will be calculated using diaphragmatic thicknesses obtained from lung ultrasound

    Time frame: 1 day during Nasal Intermittent Positive-Pressure Ventilation (NIPPV) period and 1 day during the Non-Invasive Neurally Adjusted Ventilatory Assist (NIV-NAVA) period

  6. Diaphragmatic excursion (DE)

    Measurement of Diaphragmatic excursion (DE) using lung ultrasound

    Time frame: 1 day during Nasal Intermittent Positive-Pressure Ventilation (NIPPV) period and 1 day during the Non-Invasive Neurally Adjusted Ventilatory Assist (NIV-NAVA) period

  7. Lung Ultrasound Severity Score (LUSS)

    Point score based on qualitative analysis using lung ultrasound. For each lung area, a 0- to 3-point score is given. Where 0 score refer to normal aeration and 3 score refer to severe loss of lung aeration. Total score ranging from 0-18 based on 3 areas on each lung, with low score means good lung aeration and higher means poor lung aeration.

    Time frame: 1 day during Nasal Intermittent Positive-Pressure Ventilation (NIPPV) period and 1 day during the Non-Invasive Neurally Adjusted Ventilatory Assist (NIV-NAVA) period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05589831
Lead sponsor
Mount Sinai Hospital, Canada
Responsible party
Sponsor
First posted
Oct 21, 2022
Start date
Jul 4, 2023
Primary completion
Dec 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Mar 24, 2025

Study contacts

Poorva Deshpande
Contact
poorva.deshpande@sinaihealth.ca
416-586-4800 ext. 7213
Thaiani Wulff
Contact
thaiani.wulff@sinaihealth.ca
416-586-4800 ext. 6746
Poorva Deshpande
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion